In line with this, a subgroup of patients with KRAS and TP53 mutually mutated tumors, especially those with variants having the HIGH functional effect prediction for TP53 (n = 5), may benefit from anti-PD-L1 therapy, e.g., with atezolizumab, combined with bevacizumab and chemotherapy as recently demonstrated in non-small-cell lung cancer [39]. Here, KRAS is linked to non-small cell lung carcinoma.